Home > Formulary : Adult > Recent Decisions > 2012 >
Decisions 5th December 2012
Recent JFG Decisions
At the meeting on the 5th December 2012 following actions / changes to the formulary were agreed:
New drug Requests
Tapentadol IR for acute pain
- Not approved
Eplerenone (license extension)
- Approved – TLS amber 1 month
Flutiform® (Fluticasone and Formoterol)
- Approved – TLS Green
Gabapentin in chronic cough
- Approved for use only with patients with idiopathic pulmonary fibrosis after trial with codeine linctus and dextromethorphan – TLS Red, Consultant use only, NBT only
Thalidomide in Cough
- Approved for use in patients with idiopathic pulmonary fibrosis after Gabapentin - TLS Red, Consultatnt use only, NBT only
Ropivacaine 0.75%
- Approved for patients undergoing cranitomy and awake craniotomy – TLS Red
Glycopyrronium (Seebri®) inhaler
- Approved - TLS Green
Aclidinium (Eklira®)
- Approved – TLS Green
Tolvaptan
- Approved for use by Consultant endocrinologist for acutely ill patients with SIADH for 4 to 10 days – TLS Red. It was not approved for the use in chronic patients requiring this drug.
Forceval soluble
- Approved for patients with high risk of refeeding syndrome and gastrectomy / sleeve gastrectomy - TLS Red. Phelxy-Vits® to be removed from formulary. Also approved as TLS Green to ensure nutritional adequacy for patients with dysphagia in both adults children.
Cacit D3 effervescent Granules
- TLS Green
New / Updated Shared Care Protocols
- Ticagrelor - change from amber to amber 1 month, SCP updated
- Tobramycin for chronic infections not including cystic fibrosis patients.
- Penicillamine Renal NBT updated
- Sevelamer (Renegel®) NBT Renal updated
Other Decisions /Changes
Evicel NBT Surgical Glue
- This NDR for NBT was approved at the JFG meeting 2nd October 2012 but they no longer wish to use it. To be removed from formulary for NBT.
Mezavant XL®
- This drug had been removed from the formulary following the NDR for Octasa®. It was agreed the use of this drug in patients who failed to comply with a divided daily dose regimen - TLS Blue
Tobramycin Podhaler
- Decision was deferred from 2nd October meeting awaiting comparative costings. It was agreed to add to formulary - TLS Red.